SLC20A2 and bilateral striopallidodentate calcinosis: Considering that SLC20A2 gene dosage might affect neurobehavioral impairments through brain calcification and dominant inheritance of patients with SLC20A2-PFBC, gene therapy for promoting WT allele expression might be a reasonable therapeutic option to manage this disease (Keasey et al., 2016; Matharu et al., 2019; Rabiee et al., 2020).